Primecap Management Co. CA Sells 617,620 Shares of Health Catalyst, Inc. $HCAT

Primecap Management Co. CA cut its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 31.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,369,067 shares of the company’s stock after selling 617,620 shares during the quarter. Primecap Management Co. CA owned about 1.95% of Health Catalyst worth $3,902,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. AQR Capital Management LLC lifted its position in Health Catalyst by 816.8% during the first quarter. AQR Capital Management LLC now owns 168,344 shares of the company’s stock valued at $763,000 after buying an additional 149,981 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Health Catalyst by 7.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock worth $163,000 after acquiring an additional 2,624 shares in the last quarter. Focus Partners Wealth bought a new position in shares of Health Catalyst in the 1st quarter worth about $46,000. AMH Equity Ltd lifted its position in Health Catalyst by 69.2% during the 2nd quarter. AMH Equity Ltd now owns 427,149 shares of the company’s stock valued at $1,610,000 after acquiring an additional 174,649 shares during the period. Finally, Palogic Value Management L.P. boosted its stake in Health Catalyst by 12.3% during the second quarter. Palogic Value Management L.P. now owns 730,100 shares of the company’s stock worth $2,752,000 after acquiring an additional 80,100 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Performance

Shares of HCAT opened at $1.62 on Friday. The company has a market cap of $114.58 million, a price-to-earnings ratio of -1.02 and a beta of 1.73. The business’s fifty day simple moving average is $2.17 and its two-hundred day simple moving average is $2.65. Health Catalyst, Inc. has a 12 month low of $1.61 and a 12 month high of $5.06. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.46.

Insiders Place Their Bets

In related news, General Counsel Benjamin Landry sold 27,425 shares of the stock in a transaction on Friday, December 5th. The stock was sold at an average price of $2.64, for a total transaction of $72,402.00. Following the sale, the general counsel directly owned 100,000 shares of the company’s stock, valued at $264,000. This trade represents a 21.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Julie Larson-Green sold 47,997 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $2.67, for a total value of $128,151.99. Following the completion of the transaction, the director directly owned 73,573 shares of the company’s stock, valued at approximately $196,439.91. This trade represents a 39.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. William Blair reaffirmed an “outperform” rating on shares of Health Catalyst in a research note on Tuesday, November 11th. Citigroup cut their price target on Health Catalyst from $3.25 to $2.75 and set a “neutral” rating on the stock in a research note on Friday, January 9th. Stifel Nicolaus lowered their price objective on Health Catalyst from $4.50 to $3.75 and set a “hold” rating for the company in a research note on Tuesday, November 11th. Wells Fargo & Company dropped their target price on Health Catalyst from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.15.

Health Catalyst Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.